Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase IIBiomarker/Laboratory analysis, Treatment18 and overGS-US-339-0102
NCI-2013-01283, NCT01799889

Trial Description



This study will evaluate the efficacy, safety, tolerability, and pharmacodynamics of

entospletinib. Participants with the following relapsed or refractory hematologic

malignancies will be enrolled into the study: relapsed or refractory chronic lymphocytic

leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL),

follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including

lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia [LPL/WM], small lymphocytic

lymphoma [SLL], or marginal zone lymphoma [MZL]).

Eligibility Criteria

Inclusion Criteria:

Diagnosis of B-cell iNHL, DLBCL, MCL, or CLL as documented by medical records and

with histology based on criteria established by the World Health Organization

For institutions that have Phase 3 protocols studying idelalisib (GS-1101); subjects

with malignancies being studied in these protocols must have failed screening in the

respective idelalisib protocol

Prior treatment for lymphoid malignancy requiring treatment for progressive disease

Presence of radiographically measurable lymphadenopathy or extranodal lymphoid


All acute toxic effects of any prior antitumor therapy resolved to Grade ≤ 1 before

the start of study drug

Karnofsky performance status of ≥ 60

Life expectancy of at least 3 months

Exclusion Criteria:

Known histological transformation from iNHL or CLL to an aggressive form of

non-Hodgkin lymphoma (ie, Richter transformation) except if the CLL patient is

enrolling in the B-cell receptor (BCR) previously treated cohort

Known active central nervous system or leptomeningeal lymphoma

Presence of known intermediate- or high-grade myelodysplastic syndrome

Current therapy with agents that reduce gastric acidity, including but not limited to

antacids, H2 inhibitors, and proton pump inhibitors

Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of

start of study drug

Ongoing liver injury

Ongoing or recent hepatic encephalopathy

Ongoing drug-induced pneumonitis

Ongoing inflammatory bowel disease

Ongoing alcohol or drug addiction

Pregnancy or breastfeeding

History of prior allogeneic bone marrow progenitor cell or solid organ


Ongoing immunosuppressive therapy

Concurrent participation in an investigational drug trial with therapeutic intent

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators


    Trial Sites



    University of Alabama at Birmingham Cancer Center

    Andres Forero-Torres
    Principal Investigator


    City of Hope Comprehensive Cancer Center

    Robert W. Chen
    Principal Investigator


    Barbara Ann Karmanos Cancer Institute

    Jay Yang
    Principal Investigator

    New York

    Albert Einstein College of Medicine

    Ramakrishna Battini
    Principal Investigator

    North Carolina
    Chapel Hill

    University of North Carolina at Chapel Hill

    Steven I. Park
    Principal Investigator


    Case Comprehensive Cancer Center

    Mitchell Reed Smith
    Principal Investigator


    Ohio State University Comprehensive Cancer Center

    Farrukh Tauseef Awan
    Principal Investigator


    Fred Hutch/University of Washington Cancer Consortium

    Andrei R. Shustov
    Principal Investigator

    Link to the current ClinicalTrials.gov record.
    NLM Identifer NCT01799889

    Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.